Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 13/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 3/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14108643 | 0.88 | SMN1; SMN2 (0.51) | CHRM4SCDCACNA1GCACNA1HCACNA1I | |
| SCHEMBL27929449 | 0.85 | SCD (0.53) | GPR52LMNACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL14109203 | 0.84 | CDC7 (0.55) | LMNA | |
| SCHEMBL4025836 | 0.81 | CHRM4 (0.43) | GPR52CHRM4LMNACYP1A2CYP3A4 | |
| SCHEMBL4032013 | 0.79 | KLKB1 (0.56) | GPR52LMNACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL14108608 | 0.78 | CACNA1G (0.43) | GPR52CHRM4SCDCACNA1GCACNA1H | |
| SCHEMBL14108836 | 0.77 | KDM4E (0.54) | GPR52 | |
| SCHEMBL14109371 | 0.75 | ALDH1A1 (0.48) | GPR52CYP3A4 | |
| SCHEMBL14109160 | 0.73 | CDC7 (0.52) | LMNA | |
| SCHEMBL18320904 | 0.72 | SMN1; SMN2 (0.55) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054408-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | Novartis Ag (CH) | 2009-05-06 | — | — | EP | claimed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | claimed |
| CN-101460476-B | Organic compounds | NOVARTIS AG | 2013-12-04 | — | — | CN | disclosed |